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Abstract 
Background: Adjuvant imatinib is useful in patients with gastrointestinal stromal tumors (GIST) at high risk of recur-
rence. At present, the risk of recurrence is determined based on tumor size, mitotic rate, tumor site, and tumor rup-
ture. Previous studies using various biochemical pathways identified gene expression patterns that distinguish two 
subsets of aggressive fibromatosis (AF), serous ovarian carcinoma (OVCA), and clear cell renal cell carcinoma (RCC). 
These gene sets separated soft tissue sarcomas into two groups with different probabilities of developing metastatic 
disease. The present study used these gene sets to identify GIST subgroups with different probabilities of developing 
metastatic disease.
Methods: We utilized these three gene sets, hierarchical clustering, and Kaplan–Meier analysis, to examine 60 pri-
mary resected GIST samples using Agilent chip expression profiling.
Results: Hierarchical clustering using both the combined and individual AF-, OVCA-, and RCC- gene sets identified 
differences in probabilities of developing metastatic disease between the clusters defined by the first branch point 
of the clustering dendrograms (p = 0.029 for the combined gene set, p = 0.003 for the AF-gene set, p < 0.001 for the 
OVCA-gene set, and p = 0.003 for the RCC-gene set).
Conclusions: Hierarchical clustering using these gene sets identified at least two subsets of GIST with distinct clini-
cal behavior and risk of metastatic disease. The use of gene expression analysis along with other known prognostic 
factors may better predict the long-term outcome following surgery, and thus restrict the use of adjuvant therapy to 
high-risk GIST, and reduce heterogeneity among groups in clinical trials of new drugs.
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Background
Gastrointestinal stromal tumors (GISTs) are the most 
common sarcoma of the gastrointestinal tract, occur-
ring mostly in the muscular wall of the stomach or small 
bowel, where it is felt to arise from the interstitial cells 
of Cajal or similar cells [1, 2]. The primary treatment for 
GIST is surgical excision, but a significant number of 
cases recur [3, 4]. Adjuvant imatinib, a tyrosine kinase 
inhibitor, is useful in select cases of GIST based on risk 
of recurrence [5–8]. At present, the risk of recurrence 
is determined based on tumor size, mitotic rate, tumor 
site, and tumor rupture [1, 5, 8–13], as for example in the 
Miettinen risk score [11], but more accurate predictors 
would be useful to better direct therapy.
While most GISTs have mutations in the KIT gene, 
mutations in the platelet derived growth factor receptor 
alpha (PDGFRA) gene are also common [1, 2, 5, 8, 14]. 
In a small percentage of GISTs, mutations in other genes 
such as BRAF, succinate dehydrogenase (SDH), or neu-
rofibromatosis (NF) may occur [1, 5, 15–20]. The type of 
KIT or PDGFRA mutation may affect the recurrence rate 
as well as response to imatinib [5, 8]. Despite the key role 
of activating mutations of KIT or PDGFRA, GIST biol-
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Cases of KIT-mutant GIST have been reported that pre-
sent with coexisting downstream mutations [5, 8, 21, 22].
Gene expression patterns have been used to predict the 
development of metastases in soft tissue sarcoma [23–
26]. Differences in the gene expression profiles of GISTs 
with different KIT- or PDGFRA-mutant tumors have 
been reported [27, 28], and several recent studies have 
explored the use of gene expression patterns to predict 
recurrence rate of GIST [29–35].
In previously published studies using various bio-
chemical pathways, we derived gene expression profiles 
that identified two subgroups of aggressive fibromatosis 
(AF-gene set), ovarian carcinomas (OVCA-gene set), and 
clear cell renal cell carcinomas (RCC-gene set) [36–39]. 
We previously used a gene set derived from these three 
studies to separate 73 high grade soft tissue sarcoma into 
2 or 4 groups with different propensities of metastasis 
[25]. In an independent study, these gene sets were used 
to separate 309 high-grade soft tissue sarcoma into 2 or 4 
groups with different propensity of metastasis [26].
In the present study, we utilized our three gene sets to 
examine a group of 60 GISTs using Agilent chip based 
expression profiling [33]. These gene sets successfully 
separated the GIST samples into subsets with different 
probabilities of developing disease recurrence, and may 




Sixty primary tumor samples were obtained from patients 
who had surgical resection of a GIST, and patients were 
followed without treatment until tumors recurred as 
previously described [33]. Frozen samples from resected 
primary GISTs untreated until tumor recurrence were 
selected from the European GIST database CONTICAG-
IST (http://www.conticagist.org). According to French 
law at the time of the study, experiments were performed 
in agreement with the Bioethics Law 2004 800 and the 
Ethics Charter from the National Institute of Cancer; all 
subjects signed a non-opposition statement for research 
use of their sample. Total RNA was extracted from each 
frozen tumor sample, and analyzed on Agilent Whole 
human 44K Genome Oligo Array (Agilent Technolo-
gies) as previously described [33]. Patient characteristics 
were previously described [33]. These data were kindly 
provided by Dr. F. Chibon, Institute Bergonie, Bordeaux, 
France.
Gene sets
Three different previously described gene sets with lim-
ited overlap were used: the AF-gene set, OVCA-gene set, 
and RCC-gene set. These gene sets consist of 161, 173, 
and 138 known genes respectively [36–39]. The AF-gene 
set and RCC-gene set distinguished between two sub-
groups of AF samples and RCC samples, respectively. The 
OVCA-gene set distinguished borderline from invasive 
serous OVCA. These three gene sets were pooled result-
ing in a combined gene set.
Hierarchical clustering and fold‑change analysis
The AF-, OVCA-, and RCC-gene sets were used indi-
vidually or combined, to cluster the 60 primary GIST 
samples. For clustering, genes were median centered, 
normalized, and then clustered by complete hierarchical 
clustering using uncentered correlation with Eisen clus-
tering software [40] and viewed using the TreeView soft-
ware (http://www.rana.lbl.gov) [41].
Analysis of time to metastasis
For each data set, we used the Kaplan–Meier (K-M) 
method to calculate metastasis-free survival prob-
abilities, and cumulative probabilities of metastasis (one 
minus survival probabilities) at critical time points (2, 4, 
6, and 8 years). p values were calculated by using the log-
rank test for comparing different groups. p values ≤0.05 
were considered statistically significant. Analyses were 
performed in R version 3.0.1 [42].
Results
Analysis of GIST samples using the individual AF‑, OVCA‑, 
and RCC‑gene sets
We analyzed 60 GIST samples with the individual AF-, 
RCC-, and OVCA-probe sets; patient characteristics 
have been previously reported [23]. Hierarchical clus-
tering of the GIST samples using each individual gene 
set (Additional file  1: Figure S1) identified differences 
in time to metastasis when the GIST samples were ana-
lyzed as two groups defined by the first branch point of 
the clustering. For the AF-gene set, the probability of not 
developing metastases by 6  years in Group B was 0.54 
while none of the patients in Group A recurred (Fig. 1a; 
Table 1A, p = 0.003). For the OVCA-gene set, the prob-
ability of not developing metastases at 6 years was 0.20 in 
Group B vs 0.97 in group A (Fig. 1b; Table 1B, p < 0.001). 
For the RCC-gene set, the probability of not developing 
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metastases at 6 years was 0.46 for Group B and 0.90 for 
Group A (Fig. 1c; Table 1C, p = 0.003).
Analysis of GIST samples using the combined gene set
Hierarchical clustering of the GIST samples was also 
performed using the combined gene set (AF-gene set, 
OVCA-gene set, and RCC-gene set) (Fig.  1d). Kaplan–
Meier analysis was performed using the two sample sets 
defined by the first branch point. The probability of not 
developing a metastasis by 6  years was 0.59 for Group 
B, while none recurred in Group A (Fig.  1d; Table  1D, 
p = 0.029). In Group B, clustering was evident between 
two subgroups of sufficient sample size to analyze inde-
pendently (Fig.  2). The probability of not developing a 
recurrence by 6 years was 0.39 for Group B2, while none 
of the patients in Group A or Group B1 recurred (Fig. 1e; 
Table  1E, p  <  0.001 for comparisons between each of 
the 3 sets). We also grouped the samples into 2 groups 
defined as “good prognosis” or “poor prognosis”. Samples 
were defined as “good” prognosis if they were in Group 
A in the clustering by at least 2 of the 3 gene sets (AF-, 
OVCA-, or RCC; n = 30). The probability of not devel-
oping a metastasis by 6  years was 0.40 for the “poor” 
prognosis group, while none of the patients in the “good” 
prognosis group recurred (Fig. 1f; Table 1F, p < 0.001).
Effect of Miettinen risk score on probability of developing 
recurrence
As some prognostic criteria correlate with recurrence 
of GIST, we questioned whether this scoring method 
might be improved by combining it with our clustering 
patterns. When the GIST samples were analyzed accord-
ing to Miettinen risk status [11], none of the 29 patients 
in the low or very low risk groups recurred, yet 16 of 
31 patients who scored in the high- or intermediate-
risk score by Miettinen risk also did not recur (Fig.  3a; 
Table 2A).
We went back to the hierarchical clustering performed 
with each of the gene sets in Fig.  1 to determine where 
these 31 patients with high- and intermediate-risk from 
the Miettinen score had been grouped, i.e. were they in 
Group A (good prognosis) or Group B (bad prognosis) 
(Fig. 1a–d). The probability of no metastasis for these 31 
patients is shown in Fig. 3b–e and Table 2. Of interest is 
the finding that many of the 31 patients who were classi-
fied as high- or intermediate-risk by the Miettinen score 
were grouped as good prognosis using our gene sets and 
did not recur. The rate of recurrence in the “good risk” 
group was 0  % (0/8) for the AF-gene set, 14  % (2/14) 
for the OVCA-gene set, 18  % (3/17) for the RCC-gene 
set, and 0 % (0/5) for the pooled-gene set. Interestingly, 
among the “good” groups of high- and intermediate-risk 
samples defined by the AF-gene set, 0/3 high-risk and 
0/5 intermediate-risk tumors recurred; 1/5 high- and 
1/9 intermediate-risk tumors recurred in the “good” 
group identified by clustering with the OVCA-gene set, 
and 2/7 high- and 1/7 intermediate-risk tumors recurred 
when clustered with the RCC-gene set. Among the “bad” 
Fig. 1 Kaplan–Meier analysis of the time to development of 
metastases of two groups (groups A and B) defined by the first break 
point of the hierarchical clustering of 60 GIST samples. GIST samples 
were analyzed using the individual AF-gene set (a), OVCA-gene 
set (b), RCC-gene set (c), and the combined gene set (d). The time 
to development of metastasis differed between groups A and B (a, 
p = 0.003; b, p < 0.001; c, p = 0.003; and d, p = 0.029). GIST samples 
were also analyzed by separating the samples into 3 well-separated 
clusters using the combined gene set (e, p < 0.001), and by identify-
ing samples as “good” or “poor” prognosis by any 2 of the 3 gene sets 
as described in the text (f, p < 0.001)
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prognosis group defined by clustering with the AF-, 
OVCA-, and RCC- gene sets, 11/14 high- and 4/9 inter-
mediate-risk, 10/12 high- and 3/5 intermediate-risk, and 
9/10 high- and 3/7 intermediate-risk samples recurred, 
respectively.
Discussion
The biologic heterogeneity of GISTs, as with other soft 
tissue sarcomas, introduces complexities in deciding 
optimal treatment. This study used hierarchical cluster-
ing with gene sets derived from earlier studies of vari-
ous biochemical pathways in aggressive fibromatosis, 
renal cell carcinoma, and ovarian carcinoma [36–39, 
43] to examine 60 GIST samples using Agilent chip 
expression profiling. The analyses separated the GIST 
samples into at least two groups with different prob-
abilities of developing metastatic disease. Although the 
gene sets were derived using biochemical pathways, 
we did not observe simple differences in biochemical 
pathways between the groups; possibly with a larger 
sample set, more detailed biochemical differences will 
become evident. Our data suggest that appreciation of 
these GIST subsets with distinct clinical behavior could 
be used to stratify GIST patients in clinical trials and 
in patient management. Miettinen risk group classifica-
tion also identified distinct risk groups in our 60 GIST 
cases. In particular, our analysis also identified subsets 
of Miettinen high- and intermediate-risk samples that 
different in the risk of metastasis. When the high- and 
intermediate-risk GIST samples were examined with-
out the low- and very low-risk samples, the individual 
AF-gene set, OVCA-gene set, RCC-gene set, and the 
combined gene set were associated with the time to 
development of metastasis. This finding suggests that 
further characterization of recurrence risk among sam-
ples classified as high- or intermediate-risk is possible. 
Furthermore, these results validate the potential role of 
the use of these gene sets in predicting the behavior of 
heterogeneous tumor sets.
These gene sets have also been shown to separate sets 
of soft tissue sarcoma samples into groups with different 
Table 1 Probability (95 % CI) of no metastasis as a function of time
NR no recurrence, HR hazard rario, NE hazard ratio can not be estimated when one group has no events
Time (years) 2 4 6 8 HR
A. Two sample subsets defined by the AF-gene set in Fig. 1a (p = 0.003)
Group A, n = 21 NR NR NR NR Reference group
Group B, n = 39 0.76 (0.63–0.91) 0.60 (0.45–0.81) 0.54 (0.38–0.78) 0.54 (0.38–0.78) NE
B. Two sample subsets defined by the OVCA-gene set in Fig. 1b (p < 0.001)
Group A, n = 18 NR 0.97 (0.91–1.00) 0.97 (0.91–1.00) 0.97 (0.91–1.00) Reference group
Group B, n = 42 0.53 (0.34–0.81) 0.28 (0.12–0.67) 0.19 (0.06–0.61) 0.19 (0.06–0.61) 38.7 (5.0–296.9)
C. Two sample subsets defined by the RCC-gene set in Fig. 1c (p = 0.003)
Group A, n = 35 0.94 (0.86–1.00) 0.90 (0.80–1.00) 0.90 (0.80–1.00) 0.90 (0.80–1.00) Reference group
Group B, n = 25 0.71 (0.55–0.92) 0.56 (0.38–0.81) 0.46 (0.27–0.78) 0.46 (0.27–0.78) 5.4 (1.5–19.3)
D. Two sample subsets defined by the combined gene set in Fig. 1d (p = 0.029)
Group A, n = 14 NR NR NR NR Reference Group
Group B, n = 46 0.80 (0.69–0.93) 0.66 (0.52–0.84) 0.59 (0.43–0.82) 0.59 (0.43–0.82) NE
E. Three sample subsets defined by the combined gene set in Fig. 1e (p < 0.001)
Group A, n = 14 NR NR NR NR Reference Group
Group B1, n = 17 NR NR NR NR NE
Group B2, n = 29 0.68 (0.53–0.88) 0.47 (0.29–0.74) 0.39 (0.22–0.70) 0.39 (0.22–0.70) NE
F. Two sample subsets defined by the combined gene set in Fig. 1F (p < 0.001).
Good group, n = 32 NR NR NR NR Reference Group
Poor group, n = 28 0.67 (0.52–0.87) 0.48 (0.32–0.74) 0.40 (0.23–0.70) 0.40 (0.23–0.70) NE
Fig. 2 Clustering of gene expression in the 60 GIST samples. The 
samples were clustered using the probes in the pooled gene set as 
described in the text. Groups A and B (= B1 + B2) are defined by the 
first branch point in the clustering. Groups B1 and B2 are defined by 
the second branch point in Group B
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metastatic behavior [25, 26]. A gene set of 67 genes 
involved in mitosis and control of chromosome integrity, 
termed the complexity index in sarcomas (CINSARC), 
also predicts metastasis outcome in non-translocation 
dependent soft tissue sarcomas [23]. Both the gene sets 
used here and the CINSARC [23, 33] gene set identi-
fied subsets of the GIST samples that differed in time to 
recurrence. These data support the potential use of these 
gene sets to predict biological behavior in GIST as well as 
other soft tissue sarcomas. Only 11 of the 67 genes in the 
CINSARC gene set were also present in our pooled gene 
set.
Other methods of examining genetic heterogene-
ity may also be helpful. A recent study found that chro-
mosomal changes detected by comparative genomic 
hybridization (CGH) were predictive of GIST outcome 
[33]. This study, as well as a second study, also found that 
a “genomic index” calculated from the number of chro-
mosomal alterations (segmental gains and losses), and 
number of chromosomes involved was a strong predictor 
of recurrence as well [33, 44]. Another study using array-
based analysis of gene copy number separated 42 GISTs 
into 4 groups with different survival rates [35].
Conclusions
Gene expression profiles may provide a useful tech-
nique to better predict long-term outcomes after sur-
gery in patients with GIST and other sarcomas. Such 
information could be used to restrict the use of adjuvant 
therapy and reduce heterogeneity among groups in clin-
ical trials. Due to the limited sample size of our study, 
we examined the identification of only two subsets of 
the GIST sample set with different metastatic propen-
sity. The ability to detect multiple subgroups is highly 
dependent on the number of samples and the distribu-
tion of samples among the various groups. With larger 
sample sets, it may be possible to further refine classi-
fication and identify clinically useful heterogeneity. In 
addition, although gene expression analysis may provide 
a useful indicator of long-term outcomes, it should be 
used in combination with standard prognostic factors 
in order to have maximum predictive value [8]. For 
example, in this study, further characterization of recur-
rence risk among samples classified as high-or interme-
diate-risk was possible. These results also validate the 
Fig. 3 Kaplan–Meier analysis of the time to development of metasta-
ses. Kaplan–Meier analysis of the time to development of metastases 
for Miettinen risk groups of all GIST samples (a). Miettinen risk identi-
fied distinct risk groups (p < 0.001), panel a. When the 31 high- and 
intermediate-risk GIST samples from panel a were examined for their 
grouping using the individual AF-gene set (b), OVCA-gene set (c), 
RCC-gene set (d), and the combined gene set (e) in Fig. 1, the time 
to development of metastasis differed between groups A and B (b, 
p < 0.001; c, p = 0.003; d, p = 0.029; and e, p = 0.029)
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potential role of the use of these gene sets in predicting 
the behavior of heterogeneous tumor sets. Several dif-
ferent gene sets appear to separate the samples into 2 
groups with different behavior.
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